gentamicin has been researched along with Neonatal Sepsis in 29 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Neonatal Sepsis: Blood infection that occurs in an infant younger than 90 days old. Early-onset sepsis is seen in the first week of life and most often appears within 24 hours of birth. Late-onset occurs after 1 week and before 3 months of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "120 neonates aged ≤28 days admitted being treated with standard-of-care (SOC) antibiotics for sepsis: ampicillin and gentamicin between March 2018 and February 2019." | 9.51 | Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. ( Berkley, JA; Correia, E; Egondi, T; Ellis, S; Gastine, S; Kane, Z; Kipper, K; Murunga, S; Nyaoke, B; Obiero, CW; Omollo, R; Sharland, M; Standing, JF; Thitiri, J; Walker, AS; Williams, P, 2022) |
| "This study aimed to simultaneously investigate the pharmacokinetics of ampicillin and gentamicin, currently the WHO standard of care for treating neonatal sepsis." | 9.51 | Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis. ( Berkley, JA; Correia, E; Ellis, S; Gastine, S; Kane, Z; Kipper, K; Murunga, S; Nyaoke, B; Obiero, C; Readman, J; Sharland, M; Standing, JF; Thitiri, J; van den Anker, J; Williams, P, 2022) |
| "Gentamicin for the treatment of neonatal sepsis is both feasible and effective in community-based settings and can be used as an alternative to the hospitalbased care in resource compromised settings." | 8.93 | Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review. ( Agarwal, A; Chadha, N; Gupta, N; Jaiswal, N; Kaur, H; Kaur, N; Kondel, R; Kumar, A; Malhotra, S; Shafiq, N; Singh, M; Thumburu, KK, 2016) |
| "Based on in vitro susceptibilities and the concern for emergence of resistance and long-term safety, ampicillin plus gentamicin remains the recommended antibiotic regimen for early onset neonatal sepsis." | 8.31 | Ampicillin and Gentamicin Treatment for Early Onset Neonatal Sepsis: When One Size Does Not Fit All. ( Arrieta, A; Bhakta, K; Daniels, K; Morphew, T; Nieves, DJ; Osborne, S; Tran, MT, 2023) |
| "ESBL-producing Enterobacteriaceae clinical isolates found to have caused neonatal sepsis and meningitis underwent a detailed in vitro screening including susceptibility testing, chequerboard combination analysis and hollow-fibre infection model dynamic analyses using combinations of cefotaxime, ampicillin and gentamicin in combination with β-lactamase inhibitors." | 8.31 | Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. ( Acman, M; Chiu, CH; Hamawandi, A; Lindsay, JA; Readman, JB; Sharland, M; Standing, JF, 2023) |
| "Daily dosing of gentamicin using ideal body weight is effective in successful treatment of chorioamnionitis without development endometritis and/or neonatal sepsis across different ethnicities." | 7.88 | Daily dosing of gentamicin using ideal body weight for the treatment of intrapartum chorioamnionitis: a pilot study. ( Carey, J; Guan, X; Kesavan Nasir, M; Kim, J; Martingano, D; Renson, A; Singh, S, 2018) |
| "120 neonates aged ≤28 days admitted being treated with standard-of-care (SOC) antibiotics for sepsis: ampicillin and gentamicin between March 2018 and February 2019." | 5.51 | Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. ( Berkley, JA; Correia, E; Egondi, T; Ellis, S; Gastine, S; Kane, Z; Kipper, K; Murunga, S; Nyaoke, B; Obiero, CW; Omollo, R; Sharland, M; Standing, JF; Thitiri, J; Walker, AS; Williams, P, 2022) |
| "This study aimed to simultaneously investigate the pharmacokinetics of ampicillin and gentamicin, currently the WHO standard of care for treating neonatal sepsis." | 5.51 | Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis. ( Berkley, JA; Correia, E; Ellis, S; Gastine, S; Kane, Z; Kipper, K; Murunga, S; Nyaoke, B; Obiero, C; Readman, J; Sharland, M; Standing, JF; Thitiri, J; van den Anker, J; Williams, P, 2022) |
| "Gentamicin for the treatment of neonatal sepsis is both feasible and effective in community-based settings and can be used as an alternative to the hospitalbased care in resource compromised settings." | 4.93 | Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review. ( Agarwal, A; Chadha, N; Gupta, N; Jaiswal, N; Kaur, H; Kaur, N; Kondel, R; Kumar, A; Malhotra, S; Shafiq, N; Singh, M; Thumburu, KK, 2016) |
| "Based on in vitro susceptibilities and the concern for emergence of resistance and long-term safety, ampicillin plus gentamicin remains the recommended antibiotic regimen for early onset neonatal sepsis." | 4.31 | Ampicillin and Gentamicin Treatment for Early Onset Neonatal Sepsis: When One Size Does Not Fit All. ( Arrieta, A; Bhakta, K; Daniels, K; Morphew, T; Nieves, DJ; Osborne, S; Tran, MT, 2023) |
| "ESBL-producing Enterobacteriaceae clinical isolates found to have caused neonatal sepsis and meningitis underwent a detailed in vitro screening including susceptibility testing, chequerboard combination analysis and hollow-fibre infection model dynamic analyses using combinations of cefotaxime, ampicillin and gentamicin in combination with β-lactamase inhibitors." | 4.31 | Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. ( Acman, M; Chiu, CH; Hamawandi, A; Lindsay, JA; Readman, JB; Sharland, M; Standing, JF, 2023) |
| " According to our department protocol, women with isolated intrapartum fever received intravenous ampicillin, whereas women with clinical chorioamnionitis received intravenous ampicillin plus gentamicin." | 4.31 | Antibiotic treatment of women with isolated intrapartum fever vs clinical chorioamnionitis: maternal and neonatal outcomes. ( Abu Shqara, R; Frank Wolf, M; Glikman, D; Jad, S; Lowenstein, L; Rechnitzer, H, 2023) |
| "Increasing studies have reported that gentamicin (GNT) plays an essential role in sepsis; however, its underlying mechanism is still unclear." | 4.12 | Gentamicin promoted the production of CD4 ( Li, J; Li, N; Li, S; Xie, M; Xu, F, 2022) |
| "Daily dosing of gentamicin using ideal body weight is effective in successful treatment of chorioamnionitis without development endometritis and/or neonatal sepsis across different ethnicities." | 3.88 | Daily dosing of gentamicin using ideal body weight for the treatment of intrapartum chorioamnionitis: a pilot study. ( Carey, J; Guan, X; Kesavan Nasir, M; Kim, J; Martingano, D; Renson, A; Singh, S, 2018) |
| " Adverse events and outcomes were recorded until 6 months post discharge." | 2.84 | The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi. ( Banda, FM; Chiume, M; Dube, Q; Heyderman, RS; Mallewa, M; Molyneux, EM; Schwalbe, EC; Singini, I, 2017) |
| "Neonatal sepsis is a serious condition, where an adequate empiric antibiotic treatment is crucial." | 2.82 | Efficacy of empiric antibiotic treatment of late-onset neonatal sepsis caused by Enterobacteriaceae: A systematic review. ( Akselsen, AB; Sheth, CC; Veses, V, 2022) |
| "Neonatal sepsis is a major cause of morbidity and mortality." | 2.72 | Antibiotic regimens for late-onset neonatal sepsis. ( Greisen, G; Gupta, M; Jakobsen, JC; Korang, SK; Lausten-Thomsen, U; Nava, C; Safi, S, 2021) |
| "Few studies on neonatal severe bacterial infection are available in LMICs." | 1.91 | Incidence and risk factors of neonatal bacterial infections: a community-based cohort from Madagascar (2018-2021). ( Abdou, AY; Andriamarohasina, L; Andrianirina, ZZ; Collard, JM; Crucitti, T; Delarocque-Astagneau, E; Devred, I; Guillemot, D; Harimanana, A; Herindrainy, P; Hivernaud, D; Huynh, BT; Kermorvant-Duchemin, E; Rambliere, L; Randrianirina, F; Ratsima, EH, 2023) |
| "Ampicillin resistance was found in 113 cases (95%), cefotaxime 104 (87%), gentamicin 101 (85%), AmpGen 101 (85%), piperacillin-tazobactam 47 (39%), amikacin 10 (8." | 1.62 | Prevalence and risk factors for antimicrobial resistance among newborns with gram-negative sepsis. ( Abayneh, M; Akeju, O; Ambachew, R; Bekele, D; Carvalho, MJ; Chan, GJ; Gebreyohannes, Z; Goddard, FGB; Metaferia, G; Milton, R; Odumade, OA; Sands, K; Solomon, S; Thomson, K; Van Wickle, K; Walsh, TR, 2021) |
| "44 kg dosing weight." | 1.56 | Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates. ( Faldasz, JD; Myers, SR; Yu, CZ, 2020) |
| "Empirical gentamicin dosing based on serum creatinine (SCr) levels in premature and term neonates was evaluated." | 1.46 | Empirical gentamicin dosing based on serum creatinine levels in premature and term neonates. ( Alabsi, S; Antolik, TL; Cunningham, KJ; Reimer, RA, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (37.93) | 24.3611 |
| 2020's | 18 (62.07) | 2.80 |
| Authors | Studies |
|---|---|
| Størdal, EH | 1 |
| Solevåg, AL | 1 |
| Bjørnholt, JV | 1 |
| Rønnestad, A | 1 |
| Stensvold, HJ | 1 |
| Flannery, DD | 1 |
| Puopolo, KM | 1 |
| Hansen, NI | 1 |
| Gerber, JS | 1 |
| Sánchez, PJ | 1 |
| Stoll, BJ | 1 |
| Akselsen, AB | 1 |
| Sheth, CC | 1 |
| Veses, V | 1 |
| Obiero, CW | 1 |
| Williams, P | 2 |
| Murunga, S | 2 |
| Thitiri, J | 2 |
| Omollo, R | 1 |
| Walker, AS | 2 |
| Egondi, T | 1 |
| Nyaoke, B | 2 |
| Correia, E | 2 |
| Kane, Z | 2 |
| Gastine, S | 2 |
| Kipper, K | 2 |
| Standing, JF | 3 |
| Ellis, S | 2 |
| Sharland, M | 5 |
| Berkley, JA | 2 |
| Obiero, C | 1 |
| Readman, J | 1 |
| van den Anker, J | 1 |
| Reyman, M | 1 |
| van Houten, MA | 1 |
| Watson, RL | 1 |
| Chu, MLJN | 1 |
| Arp, K | 1 |
| de Waal, WJ | 1 |
| Schiering, I | 1 |
| Plötz, FB | 1 |
| Willems, RJL | 1 |
| van Schaik, W | 1 |
| Sanders, EAM | 1 |
| Bogaert, D | 1 |
| Sharland, E | 1 |
| Qazi, S | 1 |
| Heath, P | 1 |
| Balasegaram, M | 1 |
| Bielicki, J | 1 |
| Li, J | 1 |
| Xu, F | 1 |
| Li, S | 1 |
| Xie, M | 1 |
| Li, N | 1 |
| Daniels, K | 1 |
| Arrieta, A | 1 |
| Nieves, DJ | 1 |
| Bhakta, K | 1 |
| Tran, MT | 1 |
| Osborne, S | 1 |
| Morphew, T | 1 |
| Readman, JB | 1 |
| Acman, M | 1 |
| Hamawandi, A | 1 |
| Chiu, CH | 1 |
| Lindsay, JA | 1 |
| Devred, I | 1 |
| Rambliere, L | 1 |
| Herindrainy, P | 1 |
| Andriamarohasina, L | 1 |
| Harimanana, A | 1 |
| Randrianirina, F | 1 |
| Ratsima, EH | 1 |
| Hivernaud, D | 1 |
| Kermorvant-Duchemin, E | 1 |
| Andrianirina, ZZ | 1 |
| Abdou, AY | 1 |
| Delarocque-Astagneau, E | 1 |
| Guillemot, D | 1 |
| Crucitti, T | 1 |
| Collard, JM | 1 |
| Huynh, BT | 1 |
| Abu Shqara, R | 1 |
| Glikman, D | 1 |
| Jad, S | 1 |
| Rechnitzer, H | 1 |
| Lowenstein, L | 1 |
| Frank Wolf, M | 1 |
| Narayanan, N | 1 |
| Williams, RL | 1 |
| Turner, PC | 1 |
| Paul, SP | 1 |
| Yu, CZ | 1 |
| Myers, SR | 1 |
| Faldasz, JD | 1 |
| Bielicki, JA | 1 |
| Heath, PT | 1 |
| Agarwal, R | 1 |
| Turner, P | 1 |
| Cromwell, DA | 1 |
| Rabinowicz, S | 1 |
| Rubinshtein, M | 1 |
| Strauss, T | 1 |
| Barkai, G | 1 |
| Vardi, A | 1 |
| Paret, G | 1 |
| Korang, SK | 1 |
| Safi, S | 1 |
| Nava, C | 1 |
| Greisen, G | 1 |
| Gupta, M | 1 |
| Lausten-Thomsen, U | 1 |
| Jakobsen, JC | 1 |
| Solomon, S | 1 |
| Akeju, O | 1 |
| Odumade, OA | 1 |
| Ambachew, R | 1 |
| Gebreyohannes, Z | 1 |
| Van Wickle, K | 1 |
| Abayneh, M | 1 |
| Metaferia, G | 1 |
| Carvalho, MJ | 1 |
| Thomson, K | 1 |
| Sands, K | 1 |
| Walsh, TR | 1 |
| Milton, R | 1 |
| Goddard, FGB | 1 |
| Bekele, D | 1 |
| Chan, GJ | 1 |
| Antolik, TL | 1 |
| Cunningham, KJ | 1 |
| Alabsi, S | 1 |
| Reimer, RA | 1 |
| Martingano, D | 1 |
| Guan, X | 1 |
| Renson, A | 1 |
| Singh, S | 1 |
| Kesavan Nasir, M | 1 |
| Kim, J | 1 |
| Carey, J | 1 |
| Kelly, LE | 1 |
| Shivananda, S | 1 |
| Murthy, P | 1 |
| Srinivasjois, R | 1 |
| Shah, PS | 1 |
| González-Vázquez, P | 1 |
| Larrañeta, E | 1 |
| McCrudden, MTC | 1 |
| Jarrahian, C | 1 |
| Rein-Weston, A | 1 |
| Quintanar-Solares, M | 1 |
| Zehrung, D | 1 |
| McCarthy, H | 1 |
| Courtenay, AJ | 1 |
| Donnelly, RF | 1 |
| Walker, O | 1 |
| Babb, C | 1 |
| Karampatsas, K | 1 |
| Richards, J | 1 |
| Kennea, N | 1 |
| Olita'a, D | 1 |
| Barnabas, R | 1 |
| Vali Boma, G | 1 |
| Pameh, W | 1 |
| Vince, J | 1 |
| Duke, T | 1 |
| Arora, V | 1 |
| Strunk, D | 1 |
| Furqan, SH | 1 |
| Schweig, L | 1 |
| Lefaiver, C | 1 |
| George, J | 1 |
| Prazad, P | 1 |
| Berardi, A | 1 |
| Baroni, L | 1 |
| Bacchi Reggiani, ML | 1 |
| Ambretti, S | 1 |
| Biasucci, G | 1 |
| Bolognesi, S | 1 |
| Capretti, MG | 1 |
| Carretto, E | 1 |
| Ciccia, M | 1 |
| Fiorini, V | 1 |
| Fortini, C | 1 |
| Gargano, G | 1 |
| Pedna, MF | 1 |
| Rizzo, V | 1 |
| Creti, R | 1 |
| Ferrari, F | 1 |
| Jaiswal, N | 1 |
| Singh, M | 1 |
| Kondel, R | 1 |
| Kaur, N | 1 |
| Thumburu, KK | 1 |
| Kumar, A | 1 |
| Kaur, H | 1 |
| Chadha, N | 1 |
| Gupta, N | 1 |
| Agarwal, A | 1 |
| Malhotra, S | 1 |
| Shafiq, N | 1 |
| Nair, H | 1 |
| Molyneux, EM | 1 |
| Dube, Q | 1 |
| Banda, FM | 1 |
| Chiume, M | 1 |
| Singini, I | 1 |
| Mallewa, M | 1 |
| Schwalbe, EC | 1 |
| Heyderman, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis: an Open-label Safety and Pharmacokinetics Study (neoFosfo)[NCT03453177] | Phase 2 | 120 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gentamicin and Neonatal Sepsis
| Article | Year |
|---|---|
Efficacy of empiric antibiotic treatment of late-onset neonatal sepsis caused by Enterobacteriaceae: A systematic review.
Topics: Ampicillin; Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Escherichia coli; Gentamicins | 2022 |
Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries.
Topics: Anti-Bacterial Agents; Asia; Bacteria; beta-Lactams; Clinical Decision-Making; Decision Trees; Drug | 2020 |
Antibiotic regimens for late-onset neonatal sepsis.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bias; Cefazolin; Clavulanic Acid; Drug Thera | 2021 |
Antibiotics for neonates born through meconium-stained amniotic fluid.
Topics: Amikacin; Amniotic Fluid; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Gentamicins; Huma | 2017 |
Feasibility and efficacy of gentamicin for treating neonatal sepsis in community-based settings: a systematic review.
Topics: Cause of Death; Community Health Services; Developing Countries; Dose-Response Relationship, Drug; D | 2016 |
4 trials available for gentamicin and Neonatal Sepsis
| Article | Year |
|---|---|
Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload.
Topics: Anti-Bacterial Agents; Child; Fosfomycin; Gentamicins; Humans; Infant; Infant, Newborn; Neonatal Sep | 2022 |
Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis.
Topics: Ampicillin; Anti-Bacterial Agents; Escherichia coli; Gentamicins; Humans; Infant, Newborn; Neonatal | 2022 |
Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteria; Bifidobacterium; Cef | 2022 |
The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants <60 days of Age in Malawi.
Topics: Anti-Bacterial Agents; Bilirubin; Ceftriaxone; Gentamicins; Hearing Loss; Humans; Infant; Infant, Ne | 2017 |
20 other studies available for gentamicin and Neonatal Sepsis
| Article | Year |
|---|---|
Sepsis treatment options identified by 10-year study of microbial isolates and antibiotic susceptibility in a level-four neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Gentamicins; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; | 2022 |
Antimicrobial Susceptibility Profiles Among Neonatal Early-onset Sepsis Pathogens.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Gentamicins; Gestational Age; Hu | 2022 |
Can the history of empiric antibiotic treatment for neonatal sepsis inform future global trials?
Topics: Anti-Bacterial Agents; Gentamicins; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Neonata | 2022 |
Gentamicin promoted the production of CD4
Topics: Animals; Cytokines; Forkhead Transcription Factors; Gentamicins; Interleukin-10; Interleukin-2; Mice | 2022 |
Ampicillin and Gentamicin Treatment for Early Onset Neonatal Sepsis: When One Size Does Not Fit All.
Topics: Ampicillin; Anti-Bacterial Agents; Escherichia coli; Gentamicins; Humans; Infant, Newborn; Neonatal | 2023 |
Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Escherichia c | 2023 |
Incidence and risk factors of neonatal bacterial infections: a community-based cohort from Madagascar (2018-2021).
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Child; Child, Preschool; Communicable Disease | 2023 |
Antibiotic treatment of women with isolated intrapartum fever vs clinical chorioamnionitis: maternal and neonatal outcomes.
Topics: Ampicillin; Anti-Bacterial Agents; Chorioamnionitis; Endometritis; Escherichia coli; Female; Fever; | 2023 |
Early-onset neonatal sepsis caused by
Topics: Anti-Bacterial Agents; Female; Gentamicins; Humans; Infant, Newborn; Neonatal Sepsis; Penicillin G; | 2020 |
Simulated Comparison of a Bayesian Clinical Decision Support System Versus Standard of Care For Achieving Gentamicin Pharmacokinetic Targets in Neonates.
Topics: Anti-Bacterial Agents; Bayes Theorem; Birth Weight; Body Weight; Computer Simulation; Decision Suppo | 2020 |
Life Saving Extracorporeal Membrane Oxygenation Support Use in Neonatal Listeriosis.
Topics: Ampicillin; Anti-Bacterial Agents; Extracorporeal Membrane Oxygenation; Female; Gentamicins; Humans; | 2020 |
Prevalence and risk factors for antimicrobial resistance among newborns with gram-negative sepsis.
Topics: Ampicillin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Ethiopia; F | 2021 |
Empirical gentamicin dosing based on serum creatinine levels in premature and term neonates.
Topics: Anti-Bacterial Agents; Creatinine; Drug Dosage Calculations; Gentamicins; Gestational Age; Humans; I | 2017 |
Daily dosing of gentamicin using ideal body weight for the treatment of intrapartum chorioamnionitis: a pilot study.
Topics: Adult; Chorioamnionitis; Drug Administration Schedule; Endometritis; Ethnicity; Female; Gentamicins; | 2018 |
Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsis.
Topics: Administration, Cutaneous; Animals; Animals, Newborn; Anti-Bacterial Agents; Drug Delivery Systems; | 2017 |
Screening for colonisation with gentamicin-resistant Gram-negative organisms on the neonatal unit: does positive screening predict sepsis?
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Gentamicins; Gram-Negative Bacteria; Gram-Negativ | 2019 |
Simplified management protocol for term neonates after prolonged rupture of membranes in a setting with high rates of neonatal sepsis and mortality: a quality improvement study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Clinical Protocols; Developing Co | 2019 |
Optimizing antibiotic use for early onset sepsis: A tertiary NICU experience.
Topics: Ampicillin; Anti-Bacterial Agents; Antimicrobial Stewardship; Female; Gentamicins; Hospitalization; | 2019 |
The burden of early-onset sepsis in Emilia-Romagna (Italy): a 4-year, population-based study.
Topics: Ampicillin; Anti-Bacterial Agents; Birth Weight; Drug Resistance, Microbial; Escherichia coli; Esche | 2016 |
Simplified antibiotic regimens for community management of neonatal sepsis.
Topics: Anti-Bacterial Agents; Gentamicins; Humans; Neonatal Sepsis; Sepsis | 2017 |